Trial Profile

A Phase 2A, Multicenter, Open-label Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RAP 219 (Primary)
Indications Partial epilepsies
Focus Proof of concept; Therapeutic Use
Sponsors Rapport Therapeutics

Most Recent Events

21 Mar 2025 According to Rapport Therapeutics media release, the data from this study will be presented at the 2025 American Academy of Neurology Annual Meeting.
11 Mar 2025 According to a Rapport Therapeutics media release, trial remains on track to deliver topline results in the third quarter of 2025.
07 Nov 2024 According to a Rapport Therapeutics media release, topline results are expected in mid-2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com